Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-05-06
2008-05-06
Crane, L. E. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
11196921
ABSTRACT:
Methods, compositions, and kits are presented for local tissue protection during systemic administration of anticancer therapeutic agents.
REFERENCES:
patent: 5326764 (1994-07-01), Milstone et al.
patent: 6979688 (2005-12-01), Ford
patent: 6995165 (2006-02-01), Ford
[R] Barrows, parts of “Antineoplastic and Immunoactive Drugs,” Chapter 86 in Remington: The Science and Practice of Pharmacy, 20th Edition, Gennaro et al. (eds.), Lippincott, Williams & Wilkins, Baltimore, MD, 2000, only pp. 1498 and 1815 supplied.
Cao, S. et al., “5-Fluorouracil Prodrug: Role of Anabolic and Catabolic Pathway Modulation in Therapy of Colorectal Cancer,” Clinical Cancer Research, Aug. 1995, vol. 1, pp. 839-845.
Childress, J. et al., “Cutaneous Hand and Foot Toxicity Associated with Cancer Chemotherapy,” American Journal of Clinical Oncology, Oct. 2003, vol. 26, No. 5, pp. 435-436.
Chua, D. et al., “Efficacy of Capecitabine Monotherapy in Patients with recurrent and Metastatic Nasopharyngeal Carcinoma Pretreated with Platinum-Based Chemotherapy,” 2003, Proc. Am Soc. Clin. Oncol., vol. 22, p. 511.
Ehrlanger et al., “Cutaneous Absorption and Urinary Excretion of 6-14C-5-5-Fluorouracil Ointment Applicated in an Ointment to Healthy and Diseased Human Skin,” Dermatologica, 1970, vol. 140, Suppl. I., pp. 129-136.
Elasmer et al., “Case Report: Hand-Foot Syndrome Induced by Oral Fluoropyrimidine S-1,” Jpn. J. Clin. Oncol., 2001, vol. 3, No. 4, pp. 172-174.
Findlay, M. et al., “Measurement of Plasma 5-Fluorouracil By High-Performance Liquid Chromatography with Comparison of Results to Tissue Drug Levels Observed Using In Vivo 19F Magnetic Resonance Spectroscopy in Patients in Protracted Venous Infusion With or Without Interferon-α,” Annals of Oncology, 1996, vol. 7, Nos. 47-53, pp. 111-117.
Fischel, J-L. et al., “Experimental Arguments for a Better Understanding of Hand-Foot Syndrome Under Capecitabine,” Proceedings of the American Association for Cancer Research, Mar. 2004, vol. 45, p. 487 (Abstract #2119).
Fujii, S. et al., “Effect of Coadministration of Uracil or Cytosine on the Anti-Tumor Activity of Clinical Doses of 1-(2-Tetrahydrofuryl)-5-Fluorouracil and Level of 5-Fluorouracil in Rodents,” Gann, 70, Apr. 1979, pp. 209-214.
Fukushima, S. et al., “Carcinogenicity of Uracil, a Nongenotoxic Chemical, in Rats and Mice and I Rationale,” Cancer Research 52, Apr. 1, 1992, pp. 188-193.
Gallo, R. et al., “The Enzymatic Mechanisms for Deoxthymidine Synthesis in Human Leukocites,” The Journal of Clinical Investigation, 1969, vol. 48, pp. 82-93.
Goodman & Gilman, The Pharmacological Basis of Therapeutics, 9thEdition, 1996, pp. 1225-1229, McGraw-Hill, NY, NY.
Hartmann, H.R. et al., “Modulation of the Effects of Fluoropyrimidines on Toxicity and Tumor Inhibition in Rodents by Uridine and Thymidine,” Med. Oncol. & Tumor Pharmacother, Apr. 25, 1986, vol. 3, No. 2, pp. 111-118.
Hejna, M. et al., “Decrease of Duration and Symptoms in Chemotherapy-Induced Oral Mucositis by Topical GM-CSF: Results of a Prospective Randomised Trial”, European Journal of Cancer, Nov. 2001, vol. 37, No. 16, pp. 1994-2002.
Paulo Hoff, “The Tegafur-Based Dihydropyrimidine Dehydrogenase Inhibitory Fluoropyrimidines, UFT/Leucovorin (ORZEL™) AND S-1: A Review of Their Clinical Development and Therapeutic Potential,” Investigational New Drugs, 18, 2000, pp. 153-163.
Ichikawa, W. et al., “Both Gene Expression for Orotate Phosphoribosyltransferase and Its Ratio to Dihydropyrimidine Dehydrogenase Influence Outcome Following Fluoropyrimidine-Based Chemotherapy for Metastatic Colorectal Cancer,” British Journal of Cancer, (2003), 89, 2003 Cancer Research UK.
Ikenaka, K. et al., “Effect of Uracil on Metabolism of 5-Fluorouracil in Vitro,” Gann, 70, Jun. 1979, pp. 353-359.
Johnson, M. et al., “Life-Threatening Toxicity in a Dihydropyrimidine Dehydrogenase-Deficient Patient after Treatment with Topical 5-Fluorouracil,” Clinical Cancer Research, Aug. 1999, vol. 5, pp. 141-146.
Kawaguchi, Y. et al., “Studies on the Metabolism of 1-(2-Tetrahydrofuryl)-5-Fluorouracil and Uracil Co-Administered Orally to Tumor-Bearing Rats,” Gann, 71, Dec. 1980, pp. 889-899.
Leo, S. et al., “Dermatological Toxicity from Chemotherapy Containing 5-Fluorouracil,” Journal of Chemotherapy, 1994, vol. 6, No. 6, pp. 2-5.
Levy, S. et al. “A Pharmacokinetic Evaluation of 0.5% and 5% Fluorouracil Topical Cream in Patients with Actinic Keratosis,” Clinical Therapeutics, 2001, vol. 23, No. 6, pp. 908-920.
Luccioni, et al., “Pyrimidine Nucleotide Metabolism in Human Colon Carcinomas: Comparison of Normal Tissues Primary Tumors and Xenografts,” Int. J. Cancer; 58, 1994, pp. 32-37.
Mackean, M. et al., “Phase I and Pharmacologic Study of Intermittent Twice-Daily Oral Therapy with Capecitabine in Patients with Advanced and/or Metastatic Cancer,” Journal of Clinical Oncology, 1998, vol. 16, No. 9, pp. 2977-2985.
Maehara, Y. et al., “Scientific Basis for the Combination of Tegafur with Uracil,” Oncology, vol. 11 (9), Supplement No. 10, pp. 14-21, Sep. 1997.
Malet-Martino, M. et al., “Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A review,” The Oncologist, 2002, pp. 288-323, vol. 7.
Niedzwicki, J et al., “Structure-Activity Relationship of Pyrimidine Base Analogs as Ligands of Orotate Phosphoribosyltransferase,” Biochemical Pharmacology, 1984, vol. 33 (15), pp. 2383-2395.
Naguib et al., “Enzymes of Uracil Catabolism in Normal and Neoplastic Human Tissues,” Cancer Research,45, Nov. 1985, pp. 5405-5412.
Powis, G., “Anticancer Drugs: Antimetabolie Matabolism and Natural Anticancer Agents,” International Encyclopedia of Pharmacology and Therapeutics, 1994, pp. 42-50, Pergamon Press, NY, NY.
Samid, D., “Important Information About Xeloda (Capecitabine) Tablets,” Roche Laboratories Inc., Aug. 2003.
Sawada, N. et al., “Induction of Thymidine Phosphorytase Activity and Enhancement of Capecitabine Efficacy by Taxol/Taxotere in Human Cancer Xenografts,” Clinical Cancer Research, Apr. 1998, vol. 4, pp. 1013-1019.
Schilsky, R.L. et al., “Sixty-Third Meeting of the Oncologic Drug Advisory Committee,” Food and Drug Administration Center for Drug Evaluation and Research, Sep. 16, 1999.
Senff, H. et al., “Topical 5-Fluorouracil Solution in the Treatment of Warts—Clinical Experience and Percutaneous Absorption,” British Journal of Dermatology,118, 1988, pp. 409-414.
Sludden, J. et al., “Liver Dihydropyrimidine Dehydrogenase Activity in Human, Cynomolgus Monkey, Rhesus Monkey, Rhesus Monkey, Dog, Rat and Mouse,” Pharmacology, 1998, pp. 276-280, vol. 56.
Stein, J.H., Editor-in-Chief, Internal Medicine, 4thEdition, Chapters 71 and 72, 1994.
Wang, J. et al., “Oral 5-FU is a More Effective Antimetastatic Agent than UFT,” Anticancer Research 24, 2004, pp. 1353-1360.
Unknown, “Lower Dose Capecitabine is Active and Has Favorable Safety Profile in Elderly Patients with Advanced Breast Cancer,” Oncology News International, Aug. 2003, pp. 40-44.
Unknown, “Xeloda (Capecitabine) Tablets Product Label Insert,” Roche Pharmaceuticals, Apr. 2003.
Hirata, Koichi, et al, Pharmacokinetic Study of S-1, a Novel Oral Fluorouracil Antitumor Drug, Clinical Cancer Research, Aug. 1999, pp. 2000-2005, vol. 5.
Asymmetric Therapeutics, LLC
Crane L. E.
Morgan & Lewis & Bockius, LLP
LandOfFree
Methods, compositions, and kits for organ protection during... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods, compositions, and kits for organ protection during..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods, compositions, and kits for organ protection during... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3911767